Natural history of patients with untreated liver metastases from colorectal cancer

G, Bengtsson; Carlsson, Göran; Hafström, Larsolof; Jönsson, Per‐Ebbe

doi:10.1016/0002-9610(81)90057-x

Cited by 399 publications

(144 citation statements)

References 9 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…2 Thus, unresectable liver metastases continue to account for much of the morbidity and mortality in patients with CRC. 3,4 Surgical resection of liver-confined disease for patients with no evidence of disseminated disease, a resection strategy encompassing all liver disease with adequate remnant liver for recovery and medical fitness for laparotomy, is associated with a median overall survival of 44 months and a 5-year survival rate of 35%. 5 Less than 20% of patients have liver metastases amenable to resection, a rate that may improve with current chemotherapy.…”

mentioning

confidence: 99%

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Mulcahy

Lewandowski

Ibrahim

et al. 2009

Cancer

157

View full text Add to dashboard Cite

BACKGROUND:The objective of the current study was to determine the safety and efficacy of Yttrium‐90 (Y90) microsphere treatment in patients with liver‐dominant colorectal metastases.METHODS:Seventy‐two patients with unresectable hepatic colorectal metastases were treated at a targeted absorbed dose of 120 Gray (Gy). Safety and toxicity were assessed using version 3 of the National Cancer Institute Common Terminology Criteria. Response was assessed by anatomic imaging and positron emission tomography (PET). Survival from the diagnosis of hepatic metastases and first treatment were estimated using the Kaplan‐Meier method. Substratification analyses were performed.RESULTS:The median dose delivered was 118 Gy. Treatment‐related toxicities included fatigue (61%), nausea (21%), and abdominal pain (25%). Grade 3 and 4 bilirubin toxicities were observed in 9 of 72 patients (12.6%). The tumor response rate was 40.3%. The median time to hepatic progression was 15.4 months, and the median response duration was 15 months. The PET response rate was 77%. Overall survival from the first Y90 treatment was 14.5 months. Tumor replacement (≤25% vs >25%) was associated with significantly greater median survival (18.7 months vs 5.2 months). The presence of extrahepatic disease was associated negatively with overall survival (7.9 months vs 21 months). Overall survival from the date of initial hepatic metastases was 34.6 months. A subset analysis of patients who had an Eastern Cooperative Oncology Group performance status of 0 demonstrated a median survival of 42.8 months and 23.5 months from the time of hepatic metastases and Y90 treatment, respectively.CONCLUSIONS:Y90 liver therapy appears to provide sustained disease stabilization with acceptable toxicity. Asymptomatic patients with preserved liver function at the time of Y90 appeared to benefit most from treatment. Cancer 2009. © 2009 American Cancer Society.

show abstract

mentioning

confidence: 99%

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Mulcahy

Lewandowski

Ibrahim

et al. 2009

Cancer

157

View full text Add to dashboard Cite

show abstract

“…4 Nearly all patients who have metastatic disease and do not undergo resection will die from their disease within 5 years. 4,5 Systemic chemotherapy is the standard of care for patients with unresectable metastatic disease. Intravenous (iv) 5-fluorouracil/leucovorin (5-FU/LV)-based dual regimens with either irinotecan or oxaliplatin have produced increased median overall survival over treatment with 5-FU/LV alone in patients with metastatic CRC.…”

mentioning

confidence: 99%

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Bouchahda

Adam

Giacchetti

et al. 2009

Cancer

View full text Add to dashboard Cite

Original carbohydrate‐based acrylamides bearing one azide group in C‐2 or C‐6 position namely, 2‐[(2‐deoxy‐2‐azido‐α‐D‐mannopyranosyloxy)ethanamido]‐ethyl acrylamide (II) and 2‐[(6‐deoxy‐6‐azido‐α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (III), and their azide‐free analogue, 2‐[(α‐D‐glucopyranosyloxy)ethanamido]‐ethyl acrylamide (I), have been designed. Whereas the reversible addition fragmentation chain transfer (RAFT) process ensured the preparation of well‐defined glycopolymers from I, the polymerization of monomers II and III proved to be challenging at temperatures compatible with a thermally initiated radical process, due to the presumed concomitant 1,3‐cycloaddition reactions between the azide and the acrylamide moieties. In contrast to III, for which no polymer could be obtained under any conditions, performing the RAFT polymerization of II at 30 °C clearly favored the radical polymerization and conferred a controlled character to the process, affording well‐defined azide‐functionalized glycopolymers and block copolymers. The presence of numerous azide moieties was finally exploited to introduce carbohydrates onto the glycopolymer backbone through copper catalyzed azide‐alkyne cycloaddition. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

“…En el momento del diagnóstico de un cáncer colorrectal 15% a 20% de los pacientes presentan metástasis hepáticas y entre 25% y 40% las desarrollaran en el seguimiento 8,9 . Estos pacientes sin tratamiento tienen una mediana de sobrevida de 10 meses 9,10 .…”

Section: N V E S T I G a C I ó Nunclassified

“…Estos pacientes sin tratamiento tienen una mediana de sobrevida de 10 meses 9,10 . Con quimioterapia paliativa la sobrevida puede alcanzar entre 14 y 16 meses [11][12][13][14] .…”

Section: N V E S T I G a C I ó Nunclassified

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

et al. 2009

View full text Add to dashboard Cite

Outcome of surgical treatment of liver metastasis from colorectal cancer 1 (1990-1997) and period 2 (1998-2007 (77% and 55%, respectively, p =0.04), without an increase in complications (35% and 34%, respectively; p =ns), but with a better five years survival (45% and 21%, respectively, p =0.04). Conclusions: Five years survival for excision of liver metastatic colorectal cancer in our center is similar to that reported abroad. During the second period there has been a trend toward more extensive resections which was associated with a better survival, without an increase in complications or mortality (Rev Méd Chile 2009; 137: 487-96).

show abstract

Natural history of patients with untreated liver metastases from colorectal cancer

Cited by 399 publications

References 9 publications

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

Contact Info

Product

Resources

About